An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)

被引：0
|
作者：
Ahlgren, P. [1 ,2 ,3 ,4 ,5 ,6 ]
Thirlwell, M. [1 ,2 ,3 ,4 ,5 ,6 ]
O'Regan, R. [1 ,2 ,3 ,4 ,5 ,6 ]
Mormont, C. [1 ,2 ,3 ,4 ,5 ,6 ]
Levesque, L. [1 ,2 ,3 ,4 ,5 ,6 ]
Gaspo, R. [1 ,2 ,3 ,4 ,5 ,6 ]
Woloj, M. [1 ,2 ,3 ,4 ,5 ,6 ]
Bello, A. [1 ,2 ,3 ,4 ,5 ,6 ]
Martell, B. [1 ,2 ,3 ,4 ,5 ,6 ]
Leyland-Jones, B. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Ville Marie Oncol Ctr, Montreal, PQ, Canada
[2] McGill Univ, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[4] Pfizer Canada Inc, Kirkland, PQ, Canada
[5] Pfizer Oncol, New York, NY USA
[6] Emory Univ, Sch Med, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12019
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial
    Ryan, P. D.
    Neven, P.
    Blackwell, K. L.
    Dirix, L. Y.
    Barrios, C. H.
    Miller, W. H., Jr.
    Fein, L. E.
    Fenton, D.
    Benner, R. J.
    Meech, S. J.
    Paccagnella, L.
    Sleight, B.
    Yee, D.
    Goss, P. E.
    [J]. CANCER RESEARCH, 2011, 71
  • [2] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Fulvestrant (F) as first-line palliative treatment for hormone receptor (HR)- positive metastatic breast cancer
    Bartsch, R.
    Wenzel, C.
    Ziebermayr, R.
    Bago-Horvath, Z.
    Pluschnig, U.
    Dubsky, P. C.
    Rudas, M.
    Gnant, M.
    Zielinski, C.
    Steger, G. G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
    Esteva, Francisco J.
    Franco, Sandra X.
    Hagan, Maura K.
    Brewster, Abenaa M.
    Somer, Robert A.
    Williams, Will
    Florance, Allison M.
    Turner, Simon
    Stein, Steven
    Perez, Alejandra
    [J]. ONCOLOGIST, 2013, 18 (06): : 661 - 666
  • [5] A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    Sherrill, B.
    Amonkar, M.
    Sherif, B.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 275 - 275
  • [6] First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.
    Kahan, Zsuzsanna
    Petruzelka, Lubos
    Eniu, Alexandru
    Anghel, Rodica
    Koynov, Krassimir
    Vrbanec, Damir
    Lang, Istvan
    Ahlers, Silke
    Brodowicz, Thomas
    Zielinski, Christoph
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [7] An indirect comparison of aromatase inhibitors (Als) in the first line treatment of post menopausal women with hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    Kleijnen, J.
    Riemsma, R.
    Amonkar, M. M.
    Lykopoulos, K.
    Diaz, J. R.
    Forbes, C. A.
    Rea, D. W.
    [J]. EJC SUPPLEMENTS, 2010, 8 (03): : 200 - 200
  • [8] Hormone therapy versus chemotherapy as first-line treatment for estrogen receptor-positive metastatic breast cancer (MBC) patients
    Chang, T. Y.
    Lin, C.
    Lu, Y.
    Kuo, S. H.
    Huang, S.
    Huang, C.
    Cheng, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry
    Rinnerthaler, Gabriel
    Gampenrieder, Simon P.
    Tinchon, Christoph
    Petzer, Andreas Leo
    Suppan, Christoph
    Heibl, Sonja
    Voskova, Daniela
    Zabernigg, August F.
    Egle, Daniel
    Sandholzer, Margit
    Singer, Christian F.
    Roitner, Florian
    Andel, Johannes
    Hubalek, Michael
    Knauer, Michael
    Greil, Richard
    [J]. CANCER RESEARCH, 2021, 81 (04)
  • [10] MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)
    Smith, I. E.
    Biganzoli, L.
    Cortes-Funes, H.
    Franke, F.
    Kamel, Y. Mostafa
    Pierga, J. Y.
    Pritchard, K. I.
    Stroyakovs, D.
    Thomssen, C.
    Vinholes, J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 221 - 221
12345